Johnson & Johnson MedTech has announced an exclusive commercial distribution agreement in the US with Responsive Arthroscopy for expanding sports soft tissue repair solutions.
This collaboration aims to strengthen Johnson & Johnson MedTech’s sports platform and will deliver advanced soft tissue repair solutions for foot, shoulder and ankle procedures.
Go deeper with GlobalData
It will enhance Johnson & Johnson MedTech’s soft tissue portfolio to meet the growing demand for advanced solutions in the market.
This agreement will see the combination of Johnson & Johnson MedTech’s knowledge in orthopaedic innovation with the advanced technologies of responsive arthroscopy to provide a comprehensive set of tools to healthcare providers for addressing evolving needs.
Johnson & Johnson MedTech Orthopaedics company group chairman Aldo Denti said “Our relationship with Responsive Arthroscopy is a significant step in expanding our leadership in orthopaedics and advancing our sports soft tissue offerings.
“This collaboration allows us to deliver a broader range of cutting-edge tools that empower surgeons in shoulder, foot and ankle procedures. We’re excited to drive value in this rapidly growing segment and remain committed to advancing patient care in meaningful ways.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIn orthopaedics, the company focuses on robotics, joint reconstruction, spine, sports, trauma, and extremities, leveraging deep expertise to develop next-generation medical technology solutions.
This month, after years of teasing an entry into the surgical robotics space, Johnson & Johnson MedTech completed a major step in progressing its system, winning an investigational device exemption (IDE) from the US Food and Drug Administration (FDA) for the technology.
The IDE will allow the company to conduct clinical trials at US sites with the robotic surgical system called Ottava.
